Literature DB >> 24633270

Plasma total homocysteine, high-sensitivity C-reactive protein and thyroid function in metabolic syndrome patients.

C G Orluwene1, M O Mommoh.   

Abstract

AIMS AND
OBJECTIVES: The aim of our study was to examine the levels of thyroid hormones, total plasma homocysteine and C-reactive protein in metabolic syndrome patients and assess the possibility of an association between these four risk factors for cardiovascular disease. PATIENTS AND METHODS: A total of 93 subjects were recruited for this study. (48 with metabolic syndrome and 45 as the control group). Basic demographic data, components of the metabolic syndrome, thyroid hormones, high-sensitivity C-reactive protein and total plasma homocysteine were estimated for all subjects using standards methods. Appropriate statistic was used for data analysis.
RESULTS: Components of the metabolic syndrome, thyrotropin, total plasma homocysteine and high sensitivity C-reactive protein were significantly higher in the study group (P<0.05) while free thyroxine and high density lipoprotein cholesterol were significantly lower in the study group (P<0.05). The predominant type of thyroid dysfunction in the study group was sub-clinical hypothyroidism (87.5% in the study group compared to 18% in the control; P<0.05). Logistic regression showed significant association between sub-clinical hypothyroidism, total plasma homocysteine and high-sensitivity C-reactive protein in the study group.
CONCLUSION: There was a strong association between metabolic syndrome, sub- clinical hypopthyroidism, total plasma homocysteine and high-sensitivity C- reactive protein. Females are at an increased risk of this association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24633270

Source DB:  PubMed          Journal:  Niger Postgrad Med J


  1 in total

1.  Homocysteine Is a Marker of Increased Cardio-Cerebrovascular Disease Risk in Psoriatic Patients, but It Does Not Reflect the Effect of Biological Therapy in the Longitudinal Observation.

Authors:  Janette Baloghova; Eva Feketeova; Peter Kolarcik
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.